The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...

The company also announced the receipt of an IDE from the U.S. Food and Drug Administration, to conduct a clinical study examining the ...

Among patients with resected gallbladder cancer, the addition of chemoradiation to chemotherapy treatment did not improve ...

Adding CRT to chemotherapy did not improve RFS in resected gallbladder cancer in the phase 3 ACCELERATE trial.

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the ...

Epidermal growth factor receptor (EGFR) is a major driver of cancer dissemination and target for anti-cancer therapies but ...

During the first cycle of capecitabine development, three concomitant drugs were found to affect 5-FU clearance. [5] Paracetamol and morphine increased 5-FU clearance by 26% and 41%, respectively ...

Metronomic capecitabine combined with an aromatase inhibitor extends median progression-free survival to 20.9 months compared with 11.9 months for aromatase inhibitor alone in hormone receptor ...